Industry News

Granules India Ltd on Thursday said its wholly-owned subsidiary Granules Pharmaceuticals Inc. has entered into an agreement to acquire 12.5% stake in US-based drug maker USpharma Inc. but did not disclose the amount. "This investment will enable Granules to participate in product selection and have right of first refusal to market the select products which are under development by USpharma," the company said in a statement. USpharma is a..."/>
Granules to acquire 12.5% stake in US-based drug maker USpharma [Mint, New Delhi]
Wockhardt Ltd on Thursday sought shareholders' approval for raising up to Rs.1, 200 crore through issuance of non-convertible debentures on private placement basis. "In order to re-pay/pre-pay term loan availed by the company and for general corporate purposes it is proposed to issue secured or un-secured, redeemable, NCDs on private placement basis for an amount not exceeding Rs.1, 200 crore, in one or more tranches," the company said in a notice to..."/>
BRIEF: Wockhardt seeks shareholders' nod to raise up to Rs1,200 crore through NCDs [Mint, New Delhi]
India's pharma market's missing the pep [Mint, New Delhi]
Kwality Ltd Wednesday said private equity fund KKR India has agreed to invest up to Rs.520 crore in the company in a structured finance deal. Delhi-based Kwality earns more than 70% of its revenue by selling dairy products to companies such as Hindustan Unilever Ltd, ITC Ltd and Britannia Industries Ltd. The company will use the money to strengthen its own brand and expand into more profitable retail business."/>
KKR commits to invest up to Rs520 crore in Kwality [Mint, New Delhi]
St. Jude Medical and its much larger acquirer, Chicago-based health care products maker Abbott Laboratories. After market-close Tuesday, the companies alerted investors that they had received a "second request" for information about their proposed deal from the Federal Trade Commission, which regulates anticompetitive mergers and acquisitions."/>
Feds taking a close look at Abbott's proposed purchase of St. Jude Medical [Star Tribune (Minneapolis)]
ANNALY CAPITAL MANAGEMENT COMPLETES EXCHANGE OFFER FOR HATTERAS FINANCIAL SHARES US-based mortgage REIT Annaly Capital Management, Inc. has completed its exchange offer for all of the outstanding shares of common stock of Hatteras Financial Corp., the company said. In April, Annaly Capital Management and Hatteras Financial signed a definitive merger agreement under which Annaly..."/>
M and A Navigator: Deal pipeline 14 July
Zimmer Biomet Holdings, Inc. has completed its tender offer for shares of US-based medical device maker LDR Holding Corp., the company said. As of the expiration of the tender offer, 24,278,729 shares of LDR common stock had been validly tendered and not properly withdrawn, representing approximately 82.7% of the outstanding shares of LDR common stock. LDR is focused on designing and commercialising novel and proprietary surgical..."/>
Zimmer Biomet Completes Tender Offer for Medical Device Company LDR
Imprivata has entered into a definitive agreement to be acquired by an affiliate of US-based private equity investment firm Thoma Bravo, LLC, the company aid. Under the terms of the agreement, shareholders of record will receive USD 19.25 in cash per share of Imprivata common stock, which represents a 33% premium to Imprivata's last closing stock price of USD 14.50. The value of the transaction is approximately USD 544 m."/>
Thoma Bravo to Acquire Healthcare IT Security Company Imprivata in USD 544m Deal
Evolent Health, Inc. and Valence Health, Inc. have entered into a definitive agreement for Evolent to acquire the majority of Valence Health's business for approximatelyUSD 145 m, the companies said. Evolent was founded in 2011 to support providers in moving to a population health model of care delivery and to successfully manage performance-based payment arrangements. Valence Health, based inChicago, IL, was founded in 1996..."/>
Health Care Consultant Evolent Health to Acquire Competitor Valence for USD 145m
Evolent Health in a $145 million cash and stock deal. Privately held Valence was founded in 1996 and is currently majority-owned by its founders and management. It also has private equity investors that include Massachusetts-based North Bridge, Nashville, Tenn.-based Heritage Group, Menlo Park, Calif.-based GE Ventures and Boston-based Flare Capital..."/>
Valence Health to sell biggest piece of business to Evolent for $145 million [Chicago Tribune]
NuVasive opened the doors to its Liberty Lane facility to visitors for the first time Wednesday. For Montgomery County officials and the media, it was a first look at the $45 million investment the San Diego-based company is making at the 180,000- square-foot facility, the former home to robotics manufacturer Yaskawa Motoman. "This is where the magic happens-- or will happen," said Ruben Perez, NuVasive senior director of manufacturing, as he led..."/>
Manufacturer opens doors for first look [Dayton Daily News, Ohio]
Amgen and Daiichi Sankyo Company, Limited today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars."/>
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Rennova Health, Inc. today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $8,600,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The securities offered by the Company consist of Class A Units, with each Class A Unit consisting of one share of the Company's common stock and one immediately exercisable five-year warrant to..."/>
Rennova Health, Inc. Announces Pricing of $8,600,000 Public Offering
Indivior PLC commends the United States Senate and House of Representatives for their leadership in passing the Comprehensive Addiction& Recovery Act of 2016, S. 524. This bipartisan legislation signals a strong federal response to the growing public health epidemic of opioid abuse, addiction and overdose. The Company is especially encouraged that this news closely follows the final rule by the U.S."/>
Indivior Applauds Congressional Passage of Bipartisan Comprehensive Addiction & Recovery Act of 2016 (CARA)
Teva Pharmaceutical Industries said Wednesday its $40 billion deal to buy Allergan P.L.C.' s generics business is expected to close "shortly." In a Securities and Exchange Commission filing, Teva, the world's largest generic drug company by sales, said the acquisition for $33.5 billion in cash and about 100 million of Teva's shares was imminent, pending final clearance from the Federal Trade Commission which is reviewing the deal. Teva said that to meet antitrust..."/>
BRIEF: Teva shares rise on Allergan deal news [The Philadelphia Inquirer]
IMS Health Holdings, Inc. will issue its second-quarter 2016 financial results before the market opens on Wednesday, July 27, 2016. The earnings release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com. IMS Health’ s management team will host a conference call and webcast to discuss the company’ s results at 9:00 a.m. Eastern Time on July 27."/>
IMS Health to Announce Second-Quarter 2016 Results on July 27, 2016
Juno Therapeutics Inc. concerning possible violations of federal securities laws between June 4, 2016 and July 7, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 12, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here to participate."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm
Avinger, Inc. concerning possible violations of federal securities laws. If you purchased shares of Avinger and want more information, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by e-mail at joon@khanglaw.com. There has been no class certification in this case."/>
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Avinger, Inc. and Reminds Investors with Losses to Contact the Firm
Juno Therapeutics, Inc. securities between June 4, 2016 and July 7, 2016. Juno is a biopharmaceutical company that engages in the development of cell-based cancer immunotherapies. The company specializes in its chimeric antigen receptor and T cell receptor..."/>
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Juno Therapeutics, Inc. (JUNO) and Encourages Investors to Contact the Firm
Concordia International Corp., an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today provided an update to its June 28, 2016 press release relating to the potential impact on the Company's financial operations of the United Kingdom's referendum to withdraw from the European Union. Following the outcome of Brexit on June 23, 2016, Concordia continues to monitor developments related to the..."/>
Concordia International Corp. Provides Additional Disclosure in Relation to Brexit's Impact on its Business
Concordia International Corp., an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today provided an update to its June 28, 2016 press release relating to the potential impact on the Company's financial operations of the United Kingdom's referendum to withdraw from the European Union. Following the outcome of Brexit on June 23, 2016, Concordia continues to monitor developments..."/>
Concordia International Corp. Provides Additional Disclosure in Relation to Brexit's Impact on its Business
Enzymotec Ltd. Calls its 2016 Annual General Meeting of Shareholders, issued July 13, 2016 by Enzymotec Ltd., we are advised by the company of the following amendments to the release:. Paragraph 1, sentence 1 should read“ MIGDAL HA’ EMEQ, ISRAEL, July 13, 2016—— Enzymotec Ltd., today announced that it will hold its 2016 Annual General Meeting of Shareholders on Thursday, August 25, 2016 at the Company’ s offices, at Sagi 2000 Industrial Area, Migdal Ha’ Emeq 2310001,..."/>
CORRECTING and REPLACING -- Enzymotec Ltd. Calls its 2016 Annual General Meeting of Shareholders
Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the closing of its previously announced sale to certain institutional investors of 28,000,000 shares of common stock at a purchase price per share of $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common..."/>
Galena Biopharma Announces Closing of Registered Direct Offering
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that its preclinical data will be presented in a poster session at the British Association for Psychopharmacology 2016 Summer Meeting, to be held in Brighton, UK from July 17– 22, 2016.. Professor David J. Heal, Ph.D., D.Sc.,..."/>
Cara Therapeutics’ Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials735 Articles
Consumer Discretionary663 Articles
Information Technology651 Articles
Industrials484 Articles
Health Care377 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.